Nutramedic &Cosmetics
ThymoQuin -OCare Black Seed Oil Now Applicable for Oral Health ®
Thymo-Quin®-OCare is a cold-pressed, full-spectrum black seed oil standardized to 3% thymoquinone with at least 1.2% p-Cymene and less than 1.25% free fatty acids. It's oral health applications include mouth wash, toothpaste and dietary supplements.
T
riNutra and its Korean partner, HuTri Corpora tion, have announced the use of ThymoQuin®- OCare, a cold-pressed, full-spectrum black seed oil standardized to 3% thymoquinone with at least 1.2% p-Cymene (the main bio-actives in black seed with synergistic action) and less than 1.25% free fat ty acids, is now a potent ingredient for improved hali tosis (bad breath) and sensitive teeth. “We are thrilled to supply the first patent pending ThymoQuin oral health care product. ThymoQuin- OCare is a powerful, plant-based option for impro ved oral health. We have been working on this pro ject for a while, analyzing several BSO sources, and testing them in vitro compared to existing popular products. We found that the full spectrum BSO, standardized thymoquinone level, higher ratio of thymoquinone to p-cymene (at least 3:1 ) and low free fatty acids – by far, improve oral health” said Alex Chuyoun Song, CEO at HuTri Corporation. Black seed oil’s main active constituent is thymo quinone and is unstable in the presence of oxidants, like free fatty acids – which naturally occur in the plant. This leads to reduced potency of the black seed oil and rancidity. It was, therefore, a major goal of TriNutra to find a way to standardize and stabilize its black seed oil. TriNutra’s ThymoQuin is the first
cold-pressed, full-spectrum black seed oil standard ized to 3% thymoquinone and p-cymene (min. 1.2%) with very low levels of free fatty acids (FFA) (less than 1.25%). This patented composition offers po tent health benefits with increased bioavailability. ThymoQuin®-OCare is the only black seed oil that is full-spectrum and standardized to the two main actives from black seed and with low FFA. “HuTri Corporation has been a great partner in spearheading the research behind ThymoQuin’s oral health capacity which is now specially branded as ThymoQuin®-OCare,” said Morris Zelkah, CEO at TriNutra. “We are excited about the opportunity Thy moQuin®-OCare presents in this category as it con tinues to demonstrate superior results.” This announcement follows ThymoQuin’s meeting of the USP monograph standards, its European pat ent for improved stability and bioavailability, and its US patent for the composition and synergistic ef fects of ThymoQuin with Omega-3. ThymoQuin®-OCare’s oral health applications in clude, but are not limited to, mouth wash, toothpas te and dietary supplements. www.trinutra.com service@trinutra.com
43
